Arrowhead Pharmaceuticals Inc (ARWR)

Healthcare Pharmaceuticals & Medical Research Biotechnology & Medical Research

Track Share on 𝕏

Stock chart
Ticker: ARWR Exchange: NSM


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale
Past 90 days
 
Value bought
 
Value sold
 
Net insiders buying
 
Trades (buy and sell)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PS: Planned sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Total value Details
2024-04-03 2024-04-01 S Sale

Hamilton James C

Chief Discovery/Trans Medicine

Officer
6,000 -2.8%
28.03
168,180 USD 		6,000 -2.8% 28.03 168,180 USD
2024-03-20 2024-03-20 B Purchase

Lu Hongbo

Non-Executive Director
1,000 +3.1%
27.50
27,500 USD 		1,000 +3.1% 27.50 27,500 USD
2024-03-20 2024-03-19 B Purchase

Lu Hongbo

Non-Executive Director
1,000 +3.2%
28.00
28,000 USD 		1,000 +3.2% 28.00 28,000 USD
2024-03-20 2024-03-18 B Purchase

Lu Hongbo

Non-Executive Director
1,000 +3.3%
27.49
27,490 USD 		1,000 +3.3% 27.49 27,490 USD
2024-03-08 2024-03-06 S Sale

Myszkowski Kenneth Allen

Chief Financial Officer

Officer
40,000 -9.1%
35.19
1,407,600 USD 		40,000 -9.1% 35.19 1,407,600 USD
2024-02-02 2024-01-31 PS Planned sale

Anzalone Christopher Richard

Chief Executive Officer

Executive Director
19,730 -0.5%
32.71
645,368 USD 		19,730 -0.5% 32.71 645,368 USD
2024-02-02 2024-01-31 PS Planned sale

Anzalone Christopher Richard

Chief Executive Officer

Executive Director
37,769 -1.0%
32.16
1,214,651 USD 		37,769 -1.0% 32.16 1,214,651 USD
2024-01-17 2024-01-12 PS Planned sale

Hamilton James C

Chief Discovery/Trans Medicine

Officer
3,702 -1.7%
37.37
138,344 USD 		3,702 -1.7% 37.37 138,344 USD
2024-01-17 2024-01-12 PS Planned sale

Hamilton James C

Chief Discovery/Trans Medicine

Officer
4,238 -1.9%
36.47
154,560 USD 		4,238 -1.9% 36.47 154,560 USD
2024-01-16 2024-01-11 PS Planned sale

Vakiener Victoria

Non-Executive Director
1,100 -3.3%
38.84
42,724 USD 		1,100 -3.3% 38.84 42,724 USD
2024-01-16 2024-01-11 PS Planned sale

Vakiener Victoria

Non-Executive Director
3,620 -9.9%
37.87
137,089 USD 		3,620 -9.9% 37.87 137,089 USD
2024-01-16 2024-01-11 PS Planned sale

Ferrari Mauro

Non-Executive Director
1,000 -1.6%
38.63
38,630 USD 		1,000 -1.6% 38.63 38,630 USD
2024-01-16 2024-01-11 PS Planned sale

Ferrari Mauro

Non-Executive Director
2,147 -3.4%
37.80
81,157 USD 		2,147 -3.4% 37.80 81,157 USD
2024-01-16 2024-01-11 PS Planned sale

GIVEN DOUGLAS B

Non-Executive Director
1,100 -0.8%
38.55
42,405 USD 		1,100 -0.8% 38.55 42,405 USD
2024-01-16 2024-01-11 PS Planned sale

GIVEN DOUGLAS B

Non-Executive Director
1,811 -1.4%
37.76
68,383 USD 		1,811 -1.4% 37.76 68,383 USD
2024-01-16 2024-01-11 PS Planned sale

Waddill William D.

Non-Executive Director
1,300 -2.6%
38.59
50,167 USD 		1,300 -2.6% 38.59 50,167 USD
2024-01-16 2024-01-11 PS Planned sale

Waddill William D.

Non-Executive Director
2,634 -5.1%
37.81
99,592 USD 		2,634 -5.1% 37.81 99,592 USD
2024-01-08 2024-01-05 PS Planned sale

San Martin Javier

Chief Medical Officer

Officer
4,403 -2.2%
35.64
156,923 USD 		4,403 -2.2% 35.64 156,923 USD
2024-01-08 2024-01-05 PS Planned sale

San Martin Javier

Chief Medical Officer

Officer
3,100 -1.5%
35.03
108,593 USD 		3,100 -1.5% 35.03 108,593 USD
2024-01-08 2024-01-05 PS Planned sale

San Martin Javier

Chief Medical Officer

Officer
800 -0.4%
34.11
27,288 USD 		800 -0.4% 34.11 27,288 USD
2024-01-08 2024-01-05 PS Planned sale

Oliver Tracie

Chief Commercial Officer

Officer
74 -0.1%
33.89
2,508 USD 		74 -0.1% 33.89 2,508 USD
2024-01-08 2024-01-05 PS Planned sale

Myszkowski Kenneth Allen

Chief Financial Officer

Officer
8,904 -2.0%
35.65
317,428 USD 		8,904 -2.0% 35.65 317,428 USD
2024-01-08 2024-01-05 PS Planned sale

Myszkowski Kenneth Allen

Chief Financial Officer

Officer
5,800 -1.3%
34.97
202,826 USD 		5,800 -1.3% 34.97 202,826 USD
2024-01-08 2024-01-05 PS Planned sale

Myszkowski Kenneth Allen

Chief Financial Officer

Officer
1,400 -0.3%
34.04
47,656 USD 		1,400 -0.3% 34.04 47,656 USD
2024-01-05 2024-01-05 PS Planned sale

O'Brien Patrick

COO and General Counsel

Officer
12,741 -2.7%
35.65
454,217 USD 		12,741 -2.7% 35.65 454,217 USD
2024-01-05 2024-01-05 PS Planned sale

O'Brien Patrick

COO and General Counsel

Officer
8,200 -1.7%
34.99
286,918 USD 		8,200 -1.7% 34.99 286,918 USD
2024-01-05 2024-01-05 PS Planned sale

O'Brien Patrick

COO and General Counsel

Officer
1,900 -0.4%
33.99
64,581 USD 		1,900 -0.4% 33.99 64,581 USD
2024-01-05 2024-01-05 PS Planned sale

Hamilton James C

Chief Discovery/Trans Medicine
10,000 -4.4%
35.00
350,000 USD 		10,000 -4.4% 35.00 350,000 USD
2024-01-05 2024-01-05 PS Planned sale

Hamilton James C

Chief Discovery/Trans Medicine
12,343 -5.1%
35.65
440,028 USD 		12,343 -5.1% 35.65 440,028 USD
2024-01-05 2024-01-05 PS Planned sale

Hamilton James C

Chief Discovery/Trans Medicine
8,000 -3.2%
34.94
279,520 USD 		8,000 -3.2% 34.94 279,520 USD
2024-01-05 2024-01-05 PS Planned sale

Hamilton James C

Chief Discovery/Trans Medicine
1,800 -0.7%
34.00
61,200 USD 		1,800 -0.7% 34.00 61,200 USD
2024-01-05 2024-01-04 PS Planned sale

O'Brien Patrick

COO and General Counsel

Officer
1,600 -0.4%
32.63
52,208 USD 		1,600 -0.4% 32.63 52,208 USD
2024-01-05 2024-01-03 PS Planned sale

O'Brien Patrick

COO and General Counsel

Officer
1,700 -0.4%
32.65
55,505 USD 		1,700 -0.4% 32.65 55,505 USD
2024-01-05 2024-01-03 PS Planned sale

O'Brien Patrick

COO and General Counsel

Officer
400 -0.1%
33.41
13,364 USD 		400 -0.1% 33.41 13,364 USD
2024-01-05 2024-01-03 PS Planned sale

O'Brien Patrick

COO and General Counsel

Officer
2,800 -0.7%
32.52
91,056 USD 		2,800 -0.7% 32.52 91,056 USD
2024-01-05 2024-01-03 PS Planned sale

O'Brien Patrick

COO and General Counsel

Officer
3,849 -0.9%
31.83
122,514 USD 		3,849 -0.9% 31.83 122,514 USD
2024-01-05 2024-01-03 PS Planned sale

Hamilton James C

Chief Discovery/Trans Medicine
500 -0.3%
33.30
16,650 USD 		500 -0.3% 33.30 16,650 USD
2024-01-05 2024-01-03 PS Planned sale

Hamilton James C

Chief Discovery/Trans Medicine
2,300 -1.3%
32.52
74,796 USD 		2,300 -1.3% 32.52 74,796 USD
2024-01-05 2024-01-03 PS Planned sale

Hamilton James C

Chief Discovery/Trans Medicine
3,500 -1.9%
31.81
111,335 USD 		3,500 -1.9% 31.81 111,335 USD
2024-01-04 2024-01-02 PS Planned sale

Anzalone Christopher Richard

Chief Executive Officer

Executive Director
5,318 -0.1%
31.25
166,188 USD 		5,318 -0.1% 31.25 166,188 USD
2024-01-04 2024-01-02 PS Planned sale

Anzalone Christopher Richard

Chief Executive Officer

Executive Director
4,634 -0.1%
30.74
142,449 USD 		4,634 -0.1% 30.74 142,449 USD
2023-12-22 2023-12-20 PS Planned sale

Anzalone Christopher Richard

Chief Executive Officer

Executive Director
12,000 -0.3%
28.54
342,480 USD 		12,000 -0.3% 28.54 342,480 USD
2023-11-22 2023-11-20 S Sale

San Martin Javier

Chief Medical Officer

Officer
4,942 -3.6%
29.00
143,318 USD 		4,942 -3.6% 29.00 143,318 USD
2023-11-22 2023-11-20 S Sale

San Martin Javier

Chief Medical Officer

Officer
14,758 -9.7%
28.73
423,997 USD 		14,758 -9.7% 28.73 423,997 USD
2023-10-27 2023-10-25 PS Planned sale

Anzalone Christopher Richard

Chief Executive Officer

Executive Director
24,338 -0.6%
24.21
589,223 USD 		24,338 -0.6% 24.21 589,223 USD
2023-10-02 2023-09-28 S Sale

Vakiener Victoria

Non-Executive Director
1,550 -6.7%
26.33
40,812 USD 		1,550 -6.7% 26.33 40,812 USD
2023-09-20 2023-09-18 PS Planned sale

Anzalone Christopher Richard

Chief Executive Officer

Executive Director
26,232 -0.7%
28.27
741,579 USD 		26,232 -0.7% 28.27 741,579 USD
2023-09-20 2023-09-18 PS Planned sale

Anzalone Christopher Richard

Chief Executive Officer

Executive Director
31,523 -0.8%
28.00
882,644 USD 		31,523 -0.8% 28.00 882,644 USD
2023-07-06 2023-07-03 S Sale

Oliver Tracie

Chief Commercial Officer

Officer
8,925 -12.7%
35.31
315,142 USD 		8,925 -12.7% 35.31 315,142 USD
2023-07-05 2023-06-30 S Sale

Hamilton James C

Chief Discovery/Trans Medicine
3,000 -1.6%
35.53
106,590 USD 		3,000 -1.6% 35.53 106,590 USD
2023-06-29 2023-06-27 S Sale

Myszkowski Kenneth Allen

Chief Financial Officer

Officer
15,000 -3.8%
36.20
543,000 USD 		15,000 -3.8% 36.20 543,000 USD
2023-05-08 2023-05-05 S Sale

GIVEN DOUGLAS B

Non-Executive Director
6,500 -5.2%
40.90
265,850 USD 		6,500 -5.2% 40.90 265,850 USD
2023-05-05 2023-05-04 S Sale

Anzalone Christopher Richard

Chief Executive Officer

Executive Director
25,992 -0.7%
40.02
1,040,200 USD 		25,992 -0.7% 40.02 1,040,200 USD
2023-05-05 2023-05-04 S Sale

Anzalone Christopher Richard

Chief Executive Officer

Executive Director
24,008 -0.6%
38.97
935,592 USD 		24,008 -0.6% 38.97 935,592 USD
2023-05-05 2023-05-03 S Sale

Anzalone Christopher Richard

Chief Executive Officer

Executive Director
54,928 -1.4%
39.14
2,149,882 USD 		54,928 -1.4% 39.14 2,149,882 USD
2023-03-06 2023-03-03 S Sale

OLUKOTUN ADEOYE Y

Non-Executive Director
11,350 -59.1%
32.65
370,578 USD 		11,350 -59.1% 32.65 370,578 USD
2023-03-01 2023-02-27 S Sale

GIVEN DOUGLAS B

Non-Executive Director
875 -6.3%
32.62
28,543 USD 		875 -6.3% 32.62 28,543 USD
2023-01-11 2023-01-09 PS Planned sale

Waddill William D.

Non-Executive Director
3,200 -10.0%
30.00
96,000 USD 		3,200 -10.0% 30.00 96,000 USD
2023-01-06 2023-01-05 PS Planned sale

O'Brien Patrick

COO and General Counsel

Officer
7,500 -1.8%
37.39
280,425 USD 		7,500 -1.8% 37.39 280,425 USD
2023-01-06 2023-01-05 PS Planned sale

O'Brien Patrick

COO and General Counsel

Officer
7,500 -1.8%
37.39
280,425 USD 		7,500 -1.8% 37.39 280,425 USD
2023-01-06 2023-01-05 PS Planned sale

Hamilton James C

Chief Discovery/Trans Medicine
6,573 -3.3%
37.40
245,830 USD 		6,573 -3.3% 37.40 245,830 USD
2023-01-06 2023-01-05 PS Planned sale

Hamilton James C

Chief Discovery/Trans Medicine
7,230 -3.5%
37.40
270,402 USD 		7,230 -3.5% 37.40 270,402 USD
2023-01-05 2023-01-03 PS Planned sale

O'Brien Patrick

COO and General Counsel

Officer
270 -0.1%
40.53
10,943 USD 		270 -0.1% 40.53 10,943 USD
2023-01-05 2023-01-03 PS Planned sale

O'Brien Patrick

COO and General Counsel

Officer
300 -0.1%
39.55
11,865 USD 		300 -0.1% 39.55 11,865 USD
2023-01-05 2023-01-03 PS Planned sale

O'Brien Patrick

COO and General Counsel

Officer
5,286 -1.4%
38.58
203,934 USD 		5,286 -1.4% 38.58 203,934 USD
2023-01-05 2023-01-03 PS Planned sale

O'Brien Patrick

COO and General Counsel

Officer
2,894 -0.8%
37.58
108,757 USD 		2,894 -0.8% 37.58 108,757 USD
2023-01-05 2023-01-03 PS Planned sale

O'Brien Patrick

COO and General Counsel

Officer
70 -0.0%
40.80
2,856 USD 		70 -0.0% 40.80 2,856 USD
2023-01-05 2023-01-03 PS Planned sale

O'Brien Patrick

COO and General Counsel

Officer
500 -0.1%
39.74
19,870 USD 		500 -0.1% 39.74 19,870 USD
2023-01-05 2023-01-03 PS Planned sale

O'Brien Patrick

COO and General Counsel

Officer
5,527 -1.5%
38.54
213,011 USD 		5,527 -1.5% 38.54 213,011 USD
2023-01-05 2023-01-03 PS Planned sale

O'Brien Patrick

COO and General Counsel

Officer
2,653 -0.7%
37.53
99,567 USD 		2,653 -0.7% 37.53 99,567 USD
2023-01-05 2023-01-03 PS Planned sale

Hamilton James C

Chief Discovery/Trans Medicine
247 -0.2%
40.52
10,008 USD 		247 -0.2% 40.52 10,008 USD
2023-01-05 2023-01-03 PS Planned sale

Hamilton James C

Chief Discovery/Trans Medicine
300 -0.2%
39.56
11,868 USD 		300 -0.2% 39.56 11,868 USD
2023-01-05 2023-01-03 PS Planned sale

Hamilton James C

Chief Discovery/Trans Medicine
3,682 -2.5%
38.52
141,831 USD 		3,682 -2.5% 38.52 141,831 USD
2023-01-05 2023-01-03 PS Planned sale

Hamilton James C

Chief Discovery/Trans Medicine
1,642 -1.1%
37.49
61,559 USD 		1,642 -1.1% 37.49 61,559 USD
2023-01-05 2023-01-03 PS Planned sale

Hamilton James C

Chief Discovery/Trans Medicine
136 -0.1%
40.54
5,513 USD 		136 -0.1% 40.54 5,513 USD